CD163 and prostate carcinoma: Moreover, evidence in advanced prostate cancer suggests that androgen receptor signaling contributes to the recruitment and polarization of immunosuppressive myeloid cells, including CD163+ macrophages, and enhances PD−1/PD-L1 immune checkpoint pathways, thereby reinforcing an immunosuppressive microenvironment that promotes therapeutic resistance in castration-resistant disease [39].